Long-term data on current treatments for chronic hepatitis B

Gastroenterology and Hepatology

Volumn 7, Issue 3, 2011, Pages 6-7

  Brown Jr , Robert S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CREATININE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; GENOTYPE; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); SEROCONVERSION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS TITRATION;

EID: 79954458718     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Zhao S, Tang L, Fan X, Chen L, Zhou R, Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. Virol J. 2010;7:211.
2. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218-1229.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
4. Lee JM, Park JY, Kim do Y, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther. 2010;15:235-241.
5. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430.
6. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010. (Pubitemid 43357804)
7. Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology. 2010;52(S1):476A.
8. Heathcote E, Gane EJ, de Man RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Hepatology. 2010;52(S1):477A.
9. Berg T, Marcellin P, Moeller B, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxil: final week 168 results. Hepatology. 2010;52(S1):136A.